The short interest in Hims & Hers Health (NYSE:HIMS) has approached critical levels, financial data provider S3 Partners said ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Overall, though, we'd argue that HIMS's stock is in a great position to sell puts on. At this price, the options pay a ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...